Lurasidone
- Generic Name
- Lurasidone
- Brand Names
- Latuda
- Drug Type
- Small Molecule
- Chemical Formula
- C28H36N4O2S
- CAS Number
- 367514-87-2
- Unique Ingredient Identifier
- 22IC88528T
- Background
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
- Indication
Lurasidone is indicated for the treatment of schizophrenia in patients ≥13 years old. It is also indicated as a monotherapy for the treatment of bipolar depression in patients ≥10 years old, or in combination with lithium or valproate for the treatment of bipolar depression in adults.
- Associated Conditions
- Depression, Bipolar, Schizophrenia
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 817
- Registration Number
- NCT00868959
- Locations
- 🇺🇸
Clinical Innovations Inc., Santa Ana, California, United States
🇺🇸Accurate Clinical Trials, Kissimmee, Florida, United States
🇺🇸Sheppard Pratt Health System, Baltimore, Maryland, United States
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 488
- Registration Number
- NCT00790192
- Locations
- 🇺🇸
CNRI-Los Angeles. LLC, Pico Rivera, California, United States
🇺🇸Florida Clinical Research Center, Bradenton, Florida, United States
🇷🇴Spitalul de Psihiatrie Titan "Dr. Constantin Gorgos", Bdul Nicolae Grigorescu nr. 41, Bucuresti, Romania
Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2015-06-12
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT00789698
- Locations
- 🇺🇸
Florida Clinical Research Center LLC, Bradenton, Florida, United States
🇺🇸Pillar Clinical Research, Dallas, Texas, United States
🇮🇳Deenanath Mangeshkar Hospital and Research Centre, Pune, Maharastra, India
Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
- Conditions
- SchizophreniaSchizoaffective Disorder
- Interventions
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2015-06-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 629
- Registration Number
- NCT00641745
- Locations
- 🇺🇸
K&S Professional Research Services LLC, Little Rock, Arkansas, United States
🇺🇸Woodland International Research Group, LLC, Little Rock, Arkansas, United States
🇺🇸Fidelity Clinical Research Inc., North Miami, Florida, United States
Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2015-06-12
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 478
- Registration Number
- NCT00615433
- Locations
- 🇺🇸
Lousiana Clinical Research, LLC, Shreveport, Louisiana, United States
🇺🇸UCSD Medical Center, San Diego, California, United States
🇺🇸Clinical Pharmacological Studies, Inc., Cerritos, California, United States
A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2011-09-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT00549666
- Locations
- 🇺🇸
Covance Global Clinical Pharmacology, Inc., San Diego, California, United States
Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2014-06-11
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 489
- Registration Number
- NCT00549718
- Locations
- 🇺🇸
Clinical Innovations, Inc., Costa Mesa, California, United States
🇺🇸Collaborative Neuroscience Network Inc.,12772 Valley View Street,Suite 3, Garden Grove, California, United States
🇺🇸Center for Behavioral Health, LLC, Rockville, Maryland, United States
A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia
- First Posted Date
- 2004-08-02
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT00088621
- Locations
- 🇺🇸
Segal Institute for Clinical Research, North Miami, Florida, United States
🇺🇸Optimum Health Services, La Mesa, California, United States
🇺🇸Birmingham Psychiatry Pharmaceutical, Birmingham, Alabama, United States
A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia
- First Posted Date
- 2004-08-02
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT00088634
- Locations
- 🇺🇸
Birmingham Psychiatry Pharmaceutical, Birmingham, Alabama, United States
🇺🇸Summit Research Group, Little Rock, Arkansas, United States
🇺🇸Comprehensive NeuroScience, Cerritos, California, United States
Safety and Tolerability Study of Drug to Treat Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2002-08-20
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT00044005
- Locations
- 🇺🇸
University of California, Irvine, Orange, California, United States
🇺🇸University of South Florida, Tampa, Florida, United States
🇺🇸Lake Mead Hospital, North Las Vegas, Nevada, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.